Ku-Zyme (Koichi) en es it fr

Ku-Zyme (Koichi) Brand names, Ku-Zyme (Koichi) Analogs

Ku-Zyme (Koichi) Brand Names Mixture

  • No information avaliable

Ku-Zyme (Koichi) Chemical_Formula


Ku-Zyme (Koichi) RX_link


Ku-Zyme (Koichi) fda sheet

Ku-Zyme (Koichi) msds (material safety sheet)

Ku-Zyme (Koichi) Synthesis Reference

No information avaliable

Ku-Zyme (Koichi) Molecular Weight


Ku-Zyme (Koichi) Melting Point

48-50 oC (Vinogradov, A.A. et al., Protein Eng. 14:683-689 (2001)).

Ku-Zyme (Koichi) H2O Solubility

No information avaliable

Ku-Zyme (Koichi) State


Ku-Zyme (Koichi) LogP

No information avaliable

Ku-Zyme (Koichi) Dosage Forms


Ku-Zyme (Koichi) Indication

For treatment of cystic fibrosis, chronic pancreatitis, pancreatic duct blockage

Ku-Zyme (Koichi) Pharmacology

Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.

Ku-Zyme (Koichi) Absorption

No information avaliable

Ku-Zyme (Koichi) side effects and Toxicity

No information avaliable

Ku-Zyme (Koichi) Patient Information

No information avaliable

Ku-Zyme (Koichi) Organisms Affected

Humans and other mammals